Immuneering Corp计划于2025年9月29日周一就其最近公布的Atebimetinib联合Mgnp治疗一线胰腺癌患者2a期临床试验的总体生存期数据进行讨论。
Immuneering Corp计划于2025年9月29日周一就其最近公布的Atebimetinib联合Mgnp治疗一线胰腺癌患者2a期临床试验的总体生存期数据进行讨论。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.